|
|
|
|
 |
Invitrogen Sets Date for Special Meeting of Shareholders to Vote on Proposed Merger with Applied Biosystems |
| Companies mentioned in this article: |
|
Invitrogen |
|
| 8/25/2008 @ 6:15 AM
print this article -
email to a friend -
join our eNewsletter
|
 |
Invitrogen Corporation (NASDAQ:IVGN) today announced it has set the date for a special meeting of its shareholders, to consider the proposed acquisition of Applied Biosystems Inc. The special meeting of shareholders will be held on October 16, 2008, at 9 a.m., PT at Invitrogen’s headquarters, 5781 Van Allen Way, Carlsbad, Calif. 92008. Invitrogen shareholders of record as of the close of business on September 5, 2008 will be entitled to vote at the special meeting. The Company expects to commence mailing the proxy statement and all relevant materials to Invitrogen shareholders the week of September 8, 2008. Approval of both companies’ shareholders is a condition to the closing of the transaction. The transaction is also subject to the approval of the European Commission and other customary closing conditions.
As previously announced on June 12, 2008, the Boards of Directors of Invitrogen and Applied Biosystems Inc. (formerly known as Applera Corporation) approved a definitive merger agreement under which Invitrogen will acquire all of the outstanding stock of Applied Biosystems Inc. in a cash and stock transaction valued at $6.7 billion.
Stockholders who have questions about the merger or need assistance in submitting their proxy or voting their shares should contact the Company's proxy solicitor, The Altman Group, toll-free at (866) 530-8621.
About Invitrogen
Invitrogen Corporation (NASDAQ:IVGN) provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition. The company provides essential life science technologies for disease research, drug discovery, and commercial bioproduction. Invitrogen’s own research and development efforts are focused on breakthrough innovation in all major areas of biological discovery including functional genomics, proteomics, stem cells, cell therapy and cell biology – placing Invitrogen’s products in nearly every major laboratory in the world. Founded in 1987, Invitrogen is headquartered in Carlsbad, California, and conducts business in more than 70 countries around the world. The company employs approximately 4,700 scientists and other professionals and had revenues of approximately $1.3 billion in 2007. For more information, visit www.Invitrogen.com. |
| BioTech / BioMedical / Medical |
|
|
| |
| Thursday, December 4, 2008 |
 |
|
VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology Posted 9:48 AM PST
Novio Biomedical and VGX Pharmaceuticals to Highlight Recent Advances in Electroporation-Delivered DVA Vaccines at International DNA Vaccines Conference Posted 7:42 AM PST
Applied Biosystems SOLiD System Named Life Science Innovation of the Year Posted 7:41 AM PST
Ambit Biosciences to Unveil Clinical Data from its AC220 AML Trial at American Society for Hematology Annual Conference Posted 7:37 AM PST
Aperio Introduces SecondSlide Digital Slide Sharing Network Posted 7:33 AM PST
|
| |
| Wednesday, December 3, 2008 |
|
|
Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7 in Turkey Posted 7:19 PM PST
Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study Posted 7:15 PM PST
Biocept Awarded Accreditation by the College of American Pathologists Posted 7:13 PM PST
Somaxon Pharmaceuticals to Present at the RBC Capital Markets Healthcare Conference Posted 7:07 AM PST
|
| |
| Tuesday, December 2, 2008 |
|
|
Quidel Authorizes Additional $25 Million under Stock Repurchase Program Posted 4:02 PM PST
First-Ever Human Trial of DNA-Based Immunotherapy Delivered Using Inovio Biomedical’s Electroporation Technology Shows Safety and Durable Systemic Clinical Response Posted 8:54 AM PST
Applied Biosystems – Part of Life Technologies – Helps China Respond to Melamine Contamination in Dairy Products Posted 8:51 AM PST
Nirvanix Plays Supporting Role in Ooyala’s Scalable Video Management Platform Posted 8:49 AM PST
ANA598 Receives Fast Track Designation From the FDA for the Treatment of Chronic Hepatitis C Infection Posted 8:47 AM PST
Genoptix Announces Participation at the RBC Capital Markets 2008 Healthcare Conference Posted 8:25 AM PST
TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia Posted 8:24 AM PST
|
| |
| Monday, December 1, 2008 |
|
|
SpectraScience Awarded European Patent for Its Optical Biopsy System for Tissue Diagnosis Posted 4:39 PM PST
Quidel to Present at the 20th Annual Piper Jaffray Healthcare Conference Posted 4:27 PM PST
Next-Generation Noninvasive Diagnostic Technology Shown to Accurately Detect Fetal Down Syndrome in First Trimester of Pregnancy Posted 4:26 PM PST
Novelix Pharmaceuticals, Inc. Initiates Actinic Keratosis Drug Development Program Based on Topical Use of NVX-207 and Expands Intellectual Property Portfolio Posted 4:25 PM PST
Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference Posted 8:49 AM PST
Applied Nanoscience Announces Successful EPA-FIFRA Registration for NanoFense Formulation Posted 8:46 AM PST
Ceregene Announces Clinical Data From Phase 2 Clinical Trial of CERE-120 for Parkinson's Disease Posted 8:45 AM PST
Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial Posted 8:39 AM PST
PURE Bioscience and Ciba Strike New Contract for Natural Antimicrobial Posted 8:36 AM PST
TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects Posted 8:35 AM PST
DexCom Receives CE Mark Approval for the SEVEN Continuous Glucose Monitoring System European Association for the Study of Diabetes (EASD) meeting Piper Jaffray 20th Annual Health Care Conference Posted 8:29 AM PST
|
| |
| Monday, November 24, 2008 |
|
|
Visage Imaging and Viatronix Sign Comprehensive Marketing Agreement for Virtual Colonoscopy Product Posted 4:27 PM PST
New Noninvasive Prenatal Diagnostic Technology Allows Diagnosis of Inherited Diseases Such as Cystic Fibrosis Caused by Single Gene Mutations Posted 4:23 PM PST
Life Technologies to Present at J.P. Morgan Small/Mid Cap Conference Posted 4:22 PM PST
FDA Extends Review of Somaxon Pharmaceuticals’ New Drug Application for Silenor (Doxepin) by up to Three Months Posted 7:44 AM PST
International Stem Cell Corporation Partners with Absorption Systems to Commercialize Human Stem Cell-Derived Corneal Tissue for Drug Testing Posted 7:40 AM PST
|
|
|
|
|
|
FreshNews.com Jobs Change DAILY
We Have 5,000 + Job Listings! Open Your FREE Account
Employers or Job Searchers Get Started Now! Click Here
|
